The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

NEXT STORY
CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
PREV STORY
MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

OptimizeRx to Launch Real-time Financial Messaging With Modernizing Medicine, Providing Prescription Cost Savings at Point-of-Care

ROCHESTER, Mich. and BOCA RATON, Fla., Dec. 06, 2017 (GLOBE NEWSWIRE) -- OptimizeRx Corp. ...

author_avatar
NASDAQ Market News

Tonix Pharmaceuticals Achieves 50 Percent Enrollment in RALLY, the Second Phase 3 Study of TNX-102 SL for Management of Fibromyalgia

author_avatar
NASDAQ Market News

POC Diagnostics Market Size is Projected to Reach USD 36.21 Billion by 2028

author_avatar
NASDAQ Market News